Engineered immune cells take on tough leukemia in early trial
NCT ID NCT06307054
First seen Oct 31, 2025 · Last updated Jun 18, 2026 · Updated 33 times
Summary
This early-stage trial is testing a new treatment made from a person's own immune cells, called CLL-1 CAR-NK cells, for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The study aims to see if the treatment is safe and tolerable, and to get an early look at how well it works. About 24 participants aged 18 to 70 will receive the cells and be closely monitored for side effects and leukemia response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY AML are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.